CN106389789A - Western medicine composition for preventing and treating acne and preparation method of western medicine composition - Google Patents
Western medicine composition for preventing and treating acne and preparation method of western medicine composition Download PDFInfo
- Publication number
- CN106389789A CN106389789A CN201611032051.8A CN201611032051A CN106389789A CN 106389789 A CN106389789 A CN 106389789A CN 201611032051 A CN201611032051 A CN 201611032051A CN 106389789 A CN106389789 A CN 106389789A
- Authority
- CN
- China
- Prior art keywords
- parts
- western medicine
- paste
- emulsifiable paste
- tablet
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000003814 drug Substances 0.000 title claims abstract description 58
- 206010000496 acne Diseases 0.000 title claims abstract description 53
- 239000000203 mixture Substances 0.000 title claims abstract description 40
- 238000002360 preparation method Methods 0.000 title claims description 21
- 208000002874 Acne Vulgaris Diseases 0.000 title abstract description 29
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 claims abstract description 24
- 229960001727 tretinoin Drugs 0.000 claims abstract description 24
- BYBLEWFAAKGYCD-UHFFFAOYSA-N Miconazole Chemical compound ClC1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 BYBLEWFAAKGYCD-UHFFFAOYSA-N 0.000 claims abstract description 23
- -1 compound dexamethasone acetate Chemical class 0.000 claims abstract description 23
- 229960002509 miconazole Drugs 0.000 claims abstract description 23
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims abstract description 22
- YMARZQAQMVYCKC-OEMFJLHTSA-N amprenavir Chemical compound C([C@@H]([C@H](O)CN(CC(C)C)S(=O)(=O)C=1C=CC(N)=CC=1)NC(=O)O[C@@H]1COCC1)C1=CC=CC=C1 YMARZQAQMVYCKC-OEMFJLHTSA-N 0.000 claims abstract description 22
- 229960001830 amprenavir Drugs 0.000 claims abstract description 22
- 229930002330 retinoic acid Natural products 0.000 claims abstract description 22
- IWVCMVBTMGNXQD-UHFFFAOYSA-N terramycin dehydrate Natural products C1=CC=C2C(O)(C)C3C(O)C4C(N(C)C)C(O)=C(C(N)=O)C(=O)C4(O)C(O)=C3C(=O)C2=C1O IWVCMVBTMGNXQD-UHFFFAOYSA-N 0.000 claims abstract description 22
- 239000009692 xuesetong Substances 0.000 claims abstract description 22
- 229960003088 loratadine Drugs 0.000 claims abstract description 21
- JCCNYMKQOSZNPW-UHFFFAOYSA-N loratadine Chemical compound C1CN(C(=O)OCC)CCC1=C1C2=NC=CC=C2CCC2=CC(Cl)=CC=C21 JCCNYMKQOSZNPW-UHFFFAOYSA-N 0.000 claims abstract description 21
- 235000011399 aloe vera Nutrition 0.000 claims abstract description 17
- DJGAAPFSPWAYTJ-UHFFFAOYSA-M metamizole sodium Chemical compound [Na+].O=C1C(N(CS([O-])(=O)=O)C)=C(C)N(C)N1C1=CC=CC=C1 DJGAAPFSPWAYTJ-UHFFFAOYSA-M 0.000 claims abstract description 17
- 239000006071 cream Substances 0.000 claims abstract description 16
- WJOHZNCJWYWUJD-IUGZLZTKSA-N Fluocinonide Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)COC(=O)C)[C@@]2(C)C[C@@H]1O WJOHZNCJWYWUJD-IUGZLZTKSA-N 0.000 claims abstract description 15
- 229960000785 fluocinonide Drugs 0.000 claims abstract description 15
- 239000002994 raw material Substances 0.000 claims abstract description 14
- 235000020238 sunflower seed Nutrition 0.000 claims abstract description 6
- 150000001875 compounds Chemical class 0.000 claims description 49
- 241001116389 Aloe Species 0.000 claims description 16
- 239000003292 glue Substances 0.000 claims description 16
- 239000012467 final product Substances 0.000 claims description 8
- 238000010438 heat treatment Methods 0.000 claims description 8
- 239000011812 mixed powder Substances 0.000 claims description 8
- XNPAKGMQCVYQAO-UHFFFAOYSA-N [F].CC(O)=O Chemical compound [F].CC(O)=O XNPAKGMQCVYQAO-UHFFFAOYSA-N 0.000 claims 2
- 210000000481 breast Anatomy 0.000 claims 1
- 239000000463 material Substances 0.000 claims 1
- 238000003756 stirring Methods 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 18
- 235000019198 oils Nutrition 0.000 abstract description 5
- 206010061218 Inflammation Diseases 0.000 abstract description 4
- 230000004054 inflammatory process Effects 0.000 abstract description 4
- 230000037311 normal skin Effects 0.000 abstract description 4
- 231100000331 toxic Toxicity 0.000 abstract description 4
- 230000002588 toxic effect Effects 0.000 abstract description 4
- 238000011084 recovery Methods 0.000 abstract description 3
- 230000036560 skin regeneration Effects 0.000 abstract description 3
- 239000002674 ointment Substances 0.000 abstract 2
- 244000144927 Aloe barbadensis Species 0.000 abstract 1
- 235000002961 Aloe barbadensis Nutrition 0.000 abstract 1
- 244000000626 Daucus carota Species 0.000 abstract 1
- 239000004100 Oxytetracycline Substances 0.000 abstract 1
- 235000005770 birds nest Nutrition 0.000 abstract 1
- 238000013329 compounding Methods 0.000 abstract 1
- 229960003657 dexamethasone acetate Drugs 0.000 abstract 1
- 230000003467 diminishing effect Effects 0.000 abstract 1
- IWVCMVBTMGNXQD-PXOLEDIWSA-N oxytetracycline Chemical compound C1=CC=C2[C@](O)(C)[C@H]3[C@H](O)[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O IWVCMVBTMGNXQD-PXOLEDIWSA-N 0.000 abstract 1
- 229960000625 oxytetracycline Drugs 0.000 abstract 1
- 235000019366 oxytetracycline Nutrition 0.000 abstract 1
- 230000002195 synergetic effect Effects 0.000 abstract 1
- 235000005765 wild carrot Nutrition 0.000 abstract 1
- 241000700647 Variola virus Species 0.000 description 22
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 15
- 230000000052 comparative effect Effects 0.000 description 7
- 208000024891 symptom Diseases 0.000 description 7
- 239000000843 powder Substances 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 5
- 201000004624 Dermatitis Diseases 0.000 description 4
- 208000003251 Pruritus Diseases 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 208000002193 Pain Diseases 0.000 description 3
- 206010037888 Rash pustular Diseases 0.000 description 3
- 230000003325 follicular Effects 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 208000029561 pustule Diseases 0.000 description 3
- 206010012442 Dermatitis contact Diseases 0.000 description 2
- 206010015150 Erythema Diseases 0.000 description 2
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
- SHGAZHPCJJPHSC-NUEINMDLSA-N Isotretinoin Chemical compound OC(=O)C=C(C)/C=C/C=C(C)C=CC1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-NUEINMDLSA-N 0.000 description 2
- 201000009053 Neurodermatitis Diseases 0.000 description 2
- 201000004681 Psoriasis Diseases 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- 208000019802 Sexually transmitted disease Diseases 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 208000010247 contact dermatitis Diseases 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000003862 glucocorticoid Substances 0.000 description 2
- 229960005280 isotretinoin Drugs 0.000 description 2
- BDJRBEYXGGNYIS-UHFFFAOYSA-N nonanedioic acid Chemical compound OC(=O)CCCCCCCC(O)=O BDJRBEYXGGNYIS-UHFFFAOYSA-N 0.000 description 2
- 229940127234 oral contraceptive Drugs 0.000 description 2
- 239000003539 oral contraceptive agent Substances 0.000 description 2
- 208000008742 seborrheic dermatitis Diseases 0.000 description 2
- 208000017520 skin disease Diseases 0.000 description 2
- 208000004371 toothache Diseases 0.000 description 2
- SGKRLCUYIXIAHR-AKNGSSGZSA-N (4s,4ar,5s,5ar,6r,12ar)-4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1=CC=C2[C@H](C)[C@@H]([C@H](O)[C@@H]3[C@](C(O)=C(C(N)=O)C(=O)[C@H]3N(C)C)(O)C3=O)C3=C(O)C2=C1O SGKRLCUYIXIAHR-AKNGSSGZSA-N 0.000 description 1
- FFTVPQUHLQBXQZ-KVUCHLLUSA-N (4s,4as,5ar,12ar)-4,7-bis(dimethylamino)-1,10,11,12a-tetrahydroxy-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1C2=C(N(C)C)C=CC(O)=C2C(O)=C2[C@@H]1C[C@H]1[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]1(O)C2=O FFTVPQUHLQBXQZ-KVUCHLLUSA-N 0.000 description 1
- 206010063409 Acarodermatitis Diseases 0.000 description 1
- 206010000501 Acne conglobata Diseases 0.000 description 1
- 208000020154 Acnes Diseases 0.000 description 1
- 206010003399 Arthropod bite Diseases 0.000 description 1
- 206010003645 Atopy Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 239000004342 Benzoyl peroxide Substances 0.000 description 1
- 208000007190 Chlamydia Infections Diseases 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 206010008631 Cholera Diseases 0.000 description 1
- 206010011732 Cyst Diseases 0.000 description 1
- 206010048768 Dermatosis Diseases 0.000 description 1
- 101100117236 Drosophila melanogaster speck gene Proteins 0.000 description 1
- 208000031912 Endemic Flea-Borne Typhus Diseases 0.000 description 1
- 244000148064 Enicostema verticillatum Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010014979 Epidemic typhus Diseases 0.000 description 1
- 201000000297 Erysipelas Diseases 0.000 description 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 1
- 206010018691 Granuloma Diseases 0.000 description 1
- 208000031886 HIV Infections Diseases 0.000 description 1
- 229940122440 HIV protease inhibitor Drugs 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010020112 Hirsutism Diseases 0.000 description 1
- 241000725303 Human immunodeficiency virus Species 0.000 description 1
- 241000713340 Human immunodeficiency virus 2 Species 0.000 description 1
- 206010020649 Hyperkeratosis Diseases 0.000 description 1
- 208000001126 Keratosis Diseases 0.000 description 1
- GSDSWSVVBLHKDQ-JTQLQIEISA-N Levofloxacin Chemical compound C([C@@H](N1C2=C(C(C(C(O)=O)=C1)=O)C=C1F)C)OC2=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-JTQLQIEISA-N 0.000 description 1
- 206010027626 Milia Diseases 0.000 description 1
- 206010028282 Murine typhus Diseases 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- 206010028470 Mycoplasma infections Diseases 0.000 description 1
- 206010033733 Papule Diseases 0.000 description 1
- 206010035148 Plague Diseases 0.000 description 1
- 206010036049 Polycystic ovaries Diseases 0.000 description 1
- 241000186429 Propionibacterium Species 0.000 description 1
- 206010037151 Psittacosis Diseases 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- 208000034712 Rickettsia Infections Diseases 0.000 description 1
- 206010061495 Rickettsiosis Diseases 0.000 description 1
- 208000007893 Salpingitis Diseases 0.000 description 1
- 241000447727 Scabies Species 0.000 description 1
- 206010039792 Seborrhoea Diseases 0.000 description 1
- 206010039793 Seborrhoeic dermatitis Diseases 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 208000033809 Suppuration Diseases 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 206010053615 Thermal burn Diseases 0.000 description 1
- 208000034784 Tularaemia Diseases 0.000 description 1
- 208000024780 Urticaria Diseases 0.000 description 1
- 208000006374 Uterine Cervicitis Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 241000607479 Yersinia pestis Species 0.000 description 1
- OGQICQVSFDPSEI-UHFFFAOYSA-N Zorac Chemical compound N1=CC(C(=O)OCC)=CC=C1C#CC1=CC=C(SCCC2(C)C)C2=C1 OGQICQVSFDPSEI-UHFFFAOYSA-N 0.000 description 1
- 208000026816 acute arthritis Diseases 0.000 description 1
- 229960002916 adapalene Drugs 0.000 description 1
- LZCDAPDGXCYOEH-UHFFFAOYSA-N adapalene Chemical compound C1=C(C(O)=O)C=CC2=CC(C3=CC=C(C(=C3)C34CC5CC(CC(C5)C3)C4)OC)=CC=C21 LZCDAPDGXCYOEH-UHFFFAOYSA-N 0.000 description 1
- 239000003098 androgen Substances 0.000 description 1
- 230000002280 anti-androgenic effect Effects 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 230000003667 anti-reflective effect Effects 0.000 description 1
- 239000000051 antiandrogen Substances 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 235000019400 benzoyl peroxide Nutrition 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000003727 cerebral blood flow Effects 0.000 description 1
- 206010008323 cervicitis Diseases 0.000 description 1
- 201000004308 chancroid Diseases 0.000 description 1
- 208000028512 chlamydia infectious disease Diseases 0.000 description 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 229940097572 chloromycetin Drugs 0.000 description 1
- 229960002227 clindamycin Drugs 0.000 description 1
- KDLRVYVGXIQJDK-AWPVFWJPSA-N clindamycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 KDLRVYVGXIQJDK-AWPVFWJPSA-N 0.000 description 1
- 229960000978 cyproterone acetate Drugs 0.000 description 1
- 208000031513 cyst Diseases 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229960003722 doxycycline Drugs 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 201000005901 endemic typhus Diseases 0.000 description 1
- 208000028104 epidemic louse-borne typhus Diseases 0.000 description 1
- 229960003276 erythromycin Drugs 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 244000053095 fungal pathogen Species 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 239000004030 hiv protease inhibitor Substances 0.000 description 1
- 230000003463 hyperproliferative effect Effects 0.000 description 1
- 206010021198 ichthyosis Diseases 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 201000001371 inclusion conjunctivitis Diseases 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000001524 infective effect Effects 0.000 description 1
- 238000002647 laser therapy Methods 0.000 description 1
- 229960003376 levofloxacin Drugs 0.000 description 1
- 201000011486 lichen planus Diseases 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 239000003120 macrolide antibiotic agent Substances 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 230000003821 menstrual periods Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229960004023 minocycline Drugs 0.000 description 1
- 229940127249 oral antibiotic Drugs 0.000 description 1
- 201000000901 ornithosis Diseases 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 206010035116 pityriasis rubra pilaris Diseases 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 201000010065 polycystic ovary syndrome Diseases 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000001823 pruritic effect Effects 0.000 description 1
- 208000007865 relapsing fever Diseases 0.000 description 1
- 230000000552 rheumatic effect Effects 0.000 description 1
- 208000005687 scabies Diseases 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 206010039766 scrub typhus Diseases 0.000 description 1
- 230000001932 seasonal effect Effects 0.000 description 1
- 210000001732 sebaceous gland Anatomy 0.000 description 1
- 210000002374 sebum Anatomy 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 238000011272 standard treatment Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 229960000565 tazarotene Drugs 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 229940040944 tetracyclines Drugs 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 206010044325 trachoma Diseases 0.000 description 1
- 208000000143 urethritis Diseases 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/65—Tetracyclines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/203—Retinoic acids ; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4152—1,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
- A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/57—Birds; Materials from birds, e.g. eggs, feathers, egg white, egg yolk or endothelium corneum gigeriae galli
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/886—Aloeaceae (Aloe family), e.g. aloe vera
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses western medicine composition for preventing and treating acne. The western medicine composition is prepared from raw materials in parts by weight as follows: 5-8 parts of oxytetracycline tablets, 3-5 parts of analgin tablets, 5-8 parts of normal saline, 3-5 parts of compound dexamethasone acetate ointment, 3-10 parts of fluocinonide ointment, 4-6 parts of loratadine tablets, 0.5-2 parts of retinoic acid, 1-3 parts of Xuesaitong tablets, 5-10 parts of bird's nests, 1-3 parts of aloe vera gel, 2-5 parts of miconazole cream, 5-10 parts of sunflower seed oil and 1-3 parts of Amprenavir. The western medicine composition has a synergistic effect through compounding of the raw materials and can effectively inhibit acne growth, promote acne inflammation diminishing and recovery, effectively remove acne marks and promote skin regeneration; furthermore, the western medicine composition adopts the available raw materials, is low in cost, good in curative effect and convenient to apply and has few toxic and side effects; besides, the skin can become fine, smooth and elastic when the western medicine composition is applied to the normal skin.
Description
Technical field
The present invention relates to a kind of Western medicine compound treating comedo, specifically a kind of Western medicine combination of preventing and treating comedo
Thing.
Background technology
Acne is commonly called as comedo, is a kind of pilosebaceous infective inflammation, is opened on follicular orifice sebaceous gland more, once
Follicular orifice blocks, the acne of hyper-proliferative in the stimulation of excess fat acid that excessive sebum metabolism produces and enclosed environment
The effect of propionibacterium, makes skin create inflammatory reaction, therefore the clinical manifestation of small pox from light to be again hoary hair's blackhead,
Inflamed papules and pustule, cyst and tuberosity, and the rubescent small pox with suppuration is with the presence of bacterium infection.Acne is mainly apt to occur in
Teenager, very big to teen-age psychology and social influence, but tend to nature after adolescence and mitigate or fully recover.
Existing Therapeutic Method mainly includes following several：
(1) local topical medicine：Tretinoin (tretinoin emulsifiable paste, Adapalene Gel, Tazarotene gel), benzoyl peroxide
Formyl, antibioticses (clindamycin, erythromycin, chloromycetin etc.), Azelaic Acid, sulfur lotion etc..
(2) oral antibiotic：First-selected Tetracyclines (minocycline, doxycycline etc.), are secondly that Macrolide is (red mould
Element), it is to avoid select to be usually used in the antibiotic such as levofloxacin magnitude for the treatment of system infection.Usual 6～12 weeks of antibiotic regimen.
(3) oral isotretinoin：For serious acne, oral isotretinoin is standard treatment, is also to treat acne at present
Most efficient method.The course for the treatment of is to reach minimum accumulated dose 60mg/kg as target.
(4) anti-androgen therapy：As oral contraceptive Compound Cyproterone Acetate Tablets it is adaptable in women, severe acne
Patient, with the too high performance of androgen levels (as hirsutism, seborrhea etc.) or polycystic ovarian syndrome.Delayed acne and the moon
The female patient that before menstrual period, acne significantly increases also contemplates for applying oral contraceptive.
(5) oral glucocorticoid：It is mainly used in fulminant or acne conglobata, it then follows short-term, low dose and its other party
The principle of method use in conjunction.
(6) other：For the patient not being resistant to or be reluctant to accept Drug therapy it is also contemplated that naturopathy, such as light move
Power therapy (PDT), fruit acid therapy, laser therapy etc..
Existing Therapeutic Method still has that therapeutic effect is poor, the shortcoming for the treatment of cycle length, and some prices are higher, increases
Add the financial burden of people.The medicine of various treatment acnes is also occurred in that on market, but effect is very different, has
There is also serious complication and side effect, have impact on the healthy of people.Therefore, the present invention provides a kind of curative effect
The Western medicine compound good, instant effect, toxic and side effects are little, price is relatively low.
Content of the invention
It is an object of the invention to provide a kind of Western medicine compound of preventing and treating comedo, to solve to carry in above-mentioned background technology
The problem going out.
For achieving the above object, the present invention provides following technical scheme：
A kind of Western medicine compound of preventing and treating comedo, is made up of the raw material of following parts by weight：Hydroxytetracycline tablet 5-8 part, peace
It is nearly piece 3-5 part, normal saline 5-8 part, compound dexamethason acetate emulsifiable paste 3-5 part, fluocinonide cream 3-10 part, chlorine thunder
His stator 4-6 part, Retinoic acid 0.5-2 part, XUESAITONG PIAN 1-3 part, Nidus collocaliae 5-10 part, Aloe glue 1-3 part, miconazole emulsifiable paste 2-5
Part, Oleum Helianthi 5-10 part, amprenavir 1-3 part.
As the further scheme of the present invention：It is made up of the raw material of following parts by weight：6 parts of hydroxytetracycline tablet, analgin tablet
4.5 parts, 7 parts of normal saline, 4 parts of compound dexamethason acetate emulsifiable paste, 4.5 parts of fluocinonide cream, 5 parts of Loratadine Tablets,
1 part of Retinoic acid, 1.5 parts of XUESAITONG PIAN, 8 parts of Nidus collocaliae, 1.5 parts of Aloe glue, 2.5 parts of miconazole emulsifiable paste, 7 parts of Oleum Helianthi, peace Pune
2.5 parts of Wei.
A kind of preparation method of the Western medicine compound of preventing and treating comedo, preparation method is as follows：
A. hydroxytetracycline tablet, analgin tablet, normal saline, compound dexamethason acetate emulsifiable paste, acetic acid are weighed by weight
FUQINGSONG RUGAO, Loratadine Tablets, Retinoic acid, XUESAITONG PIAN, Nidus collocaliae, Aloe glue, miconazole emulsifiable paste, amprenavir and sunflower seed
Oil, standby；
C. hydroxytetracycline tablet, analgin tablet, XUESAITONG PIAN, Loratadine Tablets are pulverized last mix homogeneously, mixed
Close powder；
D. by normal saline, compound dexamethason acetate emulsifiable paste, fluocinonide cream, miconazole emulsifiable paste, Nidus collocaliae, Aloe
Glue, Retinoic acid, amprenavir mix homogeneously, obtain mix paste；
When e. Oleum Helianthi being put into vessel in heating to 30-45 DEG C, by above-mentioned mixed-powder and above-mentioned mix paste
Put into mixing in container, be sufficiently stirred for, ultrasonic vibration 5-10min, obtain final product paste Western medicine compound.
As the present invention further scheme：When Oleum Helianthi is put into vessel in heating to 35 DEG C, by above-mentioned mixing
Powder is put in container with above-mentioned mix paste and is mixed, and is sufficiently stirred for, and ultrasonic vibration 8min obtains final product paste Western medicine compound.
Compared with prior art, the invention has the beneficial effects as follows：
This Western medicine compound passes through raw material and compounds performance synergism, can effectively suppress small pox growth, promote small pox to disappear
Scorching recovery, can effectively remove acne print, promote skin regeneration；And the Western medicine compound of the present invention adopt raw material be easy to get, cost
Low, good effect, smear conveniently, toxic and side effects little；In addition, being applied on normal skin with this Western medicine compound, skin can be made to become
Obtain moist, flexible.
Specific embodiment
With reference to specific embodiment, the technical scheme of this patent is described in more detail.
Embodiment 1
A kind of Western medicine compound of preventing and treating comedo, is made up of the raw material of following parts by weight：5 parts of hydroxytetracycline tablet, An Nai
Nearly 3 parts of piece, 5 parts of normal saline, 3 parts of compound dexamethason acetate emulsifiable paste, 3 parts of fluocinonide cream, 4 parts of Loratadine Tablets,
0.5 part of Retinoic acid, 1 part of XUESAITONG PIAN, 5 parts of Nidus collocaliae, 1 part of Aloe glue, 2 parts of miconazole emulsifiable paste, 5 parts of Oleum Helianthi, amprenavir 1
Part.
A kind of preparation method of the Western medicine compound of preventing and treating comedo, preparation method is as follows：
A. hydroxytetracycline tablet, analgin tablet, normal saline, compound dexamethason acetate emulsifiable paste, acetic acid are weighed by weight
FUQINGSONG RUGAO, Loratadine Tablets, Retinoic acid, XUESAITONG PIAN, Nidus collocaliae, Aloe glue, miconazole emulsifiable paste, amprenavir and sunflower seed
Oil, standby；
C. hydroxytetracycline tablet, analgin tablet, XUESAITONG PIAN, Loratadine Tablets are pulverized last mix homogeneously, mixed
Close powder；
D. by normal saline, compound dexamethason acetate emulsifiable paste, fluocinonide cream, miconazole emulsifiable paste, Nidus collocaliae, Aloe
Glue, Retinoic acid, amprenavir mix homogeneously, obtain mix paste；
When e. Oleum Helianthi being put into vessel in heating to 30 DEG C, above-mentioned mixed-powder is put into above-mentioned mix paste
Mix in container, be sufficiently stirred for, ultrasonic vibration 5min, obtain final product paste Western medicine compound.
Embodiment 2
A kind of Western medicine compound of preventing and treating comedo, is made up of the raw material of following parts by weight：8 parts of hydroxytetracycline tablet, An Nai
Nearly 5 parts of piece, 8 parts of normal saline, 5 parts of compound dexamethason acetate emulsifiable paste, 10 parts of fluocinonide cream, 6 parts of Loratadine Tablets,
2 parts of Retinoic acid, 3 parts of XUESAITONG PIAN, 10 parts of Nidus collocaliae, 3 parts of Aloe glue, 5 parts of miconazole emulsifiable paste, 10 parts of Oleum Helianthi, amprenavir 3
Part.
A kind of preparation method of the Western medicine compound of preventing and treating comedo, preparation method is as follows：
A. hydroxytetracycline tablet, analgin tablet, normal saline, compound dexamethason acetate emulsifiable paste, acetic acid are weighed by weight
FUQINGSONG RUGAO, Loratadine Tablets, Retinoic acid, XUESAITONG PIAN, Nidus collocaliae, Aloe glue, miconazole emulsifiable paste, amprenavir and sunflower seed
Oil, standby；
C. hydroxytetracycline tablet, analgin tablet, XUESAITONG PIAN, Loratadine Tablets are pulverized last mix homogeneously, mixed
Close powder；
D. by normal saline, compound dexamethason acetate emulsifiable paste, fluocinonide cream, miconazole emulsifiable paste, Nidus collocaliae, Aloe
Glue, Retinoic acid, amprenavir mix homogeneously, obtain mix paste；
When e. Oleum Helianthi being put into vessel in heating to 45 DEG C, above-mentioned mixed-powder is put into above-mentioned mix paste
Mix in container, be sufficiently stirred for, ultrasonic vibration 10min, obtain final product paste Western medicine compound.
Embodiment 3
A kind of Western medicine compound of preventing and treating comedo, is made up of the raw material of following parts by weight：6 parts of hydroxytetracycline tablet, An Nai
Nearly 4.5 parts of piece, 7 parts of normal saline, 4 parts of compound dexamethason acetate emulsifiable paste, 4.5 parts of fluocinonide cream, Loratadine Tablets 5
Part, 1 part of Retinoic acid, 1.5 parts of XUESAITONG PIAN, 8 parts of Nidus collocaliae, 1.5 parts of Aloe glue, 2.5 parts of miconazole emulsifiable paste, 7 parts of Oleum Helianthi, peace
2.5 parts of Pune's Wei.
A kind of preparation method of the Western medicine compound of preventing and treating comedo, preparation method is as follows：
A. hydroxytetracycline tablet, analgin tablet, normal saline, compound dexamethason acetate emulsifiable paste, acetic acid are weighed by weight
FUQINGSONG RUGAO, Loratadine Tablets, Retinoic acid, XUESAITONG PIAN, Nidus collocaliae, Aloe glue, miconazole emulsifiable paste, amprenavir and sunflower seed
Oil, standby；
C. hydroxytetracycline tablet, analgin tablet, XUESAITONG PIAN, Loratadine Tablets are pulverized last mix homogeneously, mixed
Close powder；
D. by normal saline, compound dexamethason acetate emulsifiable paste, fluocinonide cream, miconazole emulsifiable paste, Nidus collocaliae, Aloe
Glue, Retinoic acid, amprenavir mix homogeneously, obtain mix paste；
When e. Oleum Helianthi being put into vessel in heating to 35 DEG C, above-mentioned mixed-powder is put into above-mentioned mix paste
Mix in container, be sufficiently stirred for, ultrasonic vibration 8min, obtain final product paste Western medicine compound.
Comparative example 1
A kind of Western medicine compound of preventing and treating comedo, is made up of the raw material of following parts by weight：6 parts of hydroxytetracycline tablet, An Nai
Nearly 4.5 parts of piece, 7 parts of normal saline, 4 parts of compound dexamethason acetate emulsifiable paste, 4.5 parts of fluocinonide cream, Loratadine Tablets 5
Part, 1 part of Retinoic acid, 1.5 parts of XUESAITONG PIAN, 8 parts of Nidus collocaliae, 1.5 parts of Aloe glue, 2.5 parts of miconazole emulsifiable paste, 7 parts of Oleum Helianthi.
A kind of preparation method of the Western medicine compound of preventing and treating comedo, preparation method is as follows：
A. hydroxytetracycline tablet, analgin tablet, normal saline, compound dexamethason acetate emulsifiable paste, acetic acid are weighed by weight
FUQINGSONG RUGAO, Loratadine Tablets, Retinoic acid, XUESAITONG PIAN, Nidus collocaliae, Aloe glue, miconazole emulsifiable paste and Oleum Helianthi, standby；
C. hydroxytetracycline tablet, analgin tablet, XUESAITONG PIAN, Loratadine Tablets are pulverized last mix homogeneously, mixed
Close powder；
D. by normal saline, compound dexamethason acetate emulsifiable paste, fluocinonide cream, miconazole emulsifiable paste, Nidus collocaliae, Aloe
Glue, Retinoic acid mix homogeneously, obtain mix paste；
When e. Oleum Helianthi being put into vessel in heating to 35 DEG C, above-mentioned mixed-powder is put into above-mentioned mix paste
Mix in container, be sufficiently stirred for, ultrasonic vibration 8min, obtain final product paste Western medicine compound.It is not added with amprenavir in comparative example 1.
The theoretical basiss of the present invention are：
Hydroxytetracycline tablet：Indication：Rickettsiosiss, including epidemic typhuses, endemic typhuss, Rocky Mountain
Heat, scrub typhus and Q heat；Mycoplasma Infections；Chlamydia infections, including psittacosis, sexually transmitted disease (STD), lymph granuloma, non-specificity
Urethritiss, salpingitis, cervicitises and trachoma；Relapsing fever；Gibraltar fever；Cholera；Tularemia；The plague；Chancroid.
Analgin tablet：It is mainly used in bringing down a fever, be also used for treating acute arthritises, headache, rheumatic pain, toothache and myalgia
Deng.
Normal saline：Mainly there is antipyretic, antiinflammatory, strengthen the effect such as immune function.
Compound dexamethason acetate emulsifiable paste：For local pruritus, neurodermatitiss, contact dermatitis, seborrheica skin
Inflammation and chronic eczema.
Fluocinonide cream：External is applied to the effective dermatosiss to glucocorticoid, such as contact dermatitis, atopy
Dermatitis, seborrheic dermatitis, eczema, skin prurituss, psoriasises, neurodermatitiss etc. are pruritic and non-infectious inflammation skin
Disease.
Loratadine Tablets：For seasonal or catarrhus perennialises, the urticaria being caused by anaphylactogen and skin scabies
Itch.
Retinoic acid：For treat acne vulgariss, psoriasises, ichthyosiss, lichen planuss, pityriasis rubra pilaris, follicular keratosis,
The disease such as squamous cell carcinoma and melanoma.
XUESAITONG PIAN：Blood circulation promoting and blood stasis dispelling, promotes blood circulation active, suppresses platelet aggregation and increases cerebral blood flow.
Nidus collocaliae：Looks improving and the skin nourishing.
Aloe glue：To incised wound, scratch, suppurating sore, scald, skin prurituss, comedo, black speck, mosquito bite, toothache,
Labial angle festers, operative scar etc. has obvious assosting effect.
Miconazole emulsifiable paste：Miconazole is efficient, safety, broad-spectrum antifungal medicine, nearly all has effect to pathogenic funguses.
Amprenavir：Amprenavir is that a kind of new anti-reflective turns hiv protease inhibitor, has anti-HIV-1 and HIV-2
Albumen enzyme effect, can block protein precursor division, the growth course of viral interference necessary to HIV maturation, then discharge
Immature do not have communicable viruses molecule.There is presently no the application finding amprenavir on treatment comedo.
Oleum Helianthi：Parasite killing can be moisturized, dissipate erysipelas, detumescence poison.
First, this Western medicine compound treats the observation of curative effect of small pox：
Clinical Selection small pox patient of the present invention 400, wherein man 170, female 230；Comedo patient 250, gets angry
Small pox patient 50, physiology phase small pox patient 50, other 50.Small pox symptom is：Redness, pain, pustule, Whiteheads,
Blackhead.Patient is divided into four groups, every group 100, respectively 1 group of embodiment, 2 groups of embodiment, 3 groups of embodiment and comparative example
Group.
Application process：1 group of embodiment smears the Western medicine compound of the embodiment of the present invention 1 preparation daily, and 2 groups of embodiment is daily
Smear the Western medicine compound of the embodiment of the present invention 2 preparation, 3 groups of embodiment smears the Western medicine group of the embodiment of the present invention 3 preparation daily
Compound, comparative example group smears the Western medicine compound of comparative example 1 of the present invention preparation daily, 3 times a day, early, middle and late respectively smears one
Secondary, clean after once keeping 15 minutes, be within 3 days a course for the treatment of.
The criterion of therapeutical effect of small pox：Effective, effective and invalid.
(1) effective：After smearing 1 course for the treatment of, small pox symptom is wholly absent, and skin recovers smooth, and no acne print produces, and one
No recur in month；
(2) effective：After smearing 1 course for the treatment of, small pox symptom is clearly better, and small pox redness, pain, pustule disappear, and smear 2
After the course for the treatment of, small pox symptom is wholly absent, and skin recovers smooth, and no acne print produces；
(3) invalid：After smearing the 3-4 course for the treatment of, small pox symptom is no improved or is increased.
Therapeutic outcome is shown in Table 1：
This Western medicine compound of table 1 treats the efficacy result of small pox
| Project | Effective/example | Effectively/example | Invalid/example | Effective percentage/% |
| 1 group of embodiment | 50 | 98 | 2 | 98 |
| 2 groups of embodiment | 47 | 97 | 3 | 97 |
| 3 groups of embodiment | 55 | 100 | 0 | 100 |
| Comparative example group | 20 | 65 | 35 | 65 |
Small pox can be effectively suppressed to grow, to small pox as it can be seen from table 1 this Western medicine compound passes through interpolation amprenavir
Antiinflammatory recovers to play great role.And this Western medicine compound is respectively provided with higher effective percentage to treating various types of small poxs.
2nd, this Western medicine compound removes the observation of curative effect of acne print：
Clinical Selection patient of the present invention 200, is the acne print that small pox healing is formed；Wherein man 80, female 120.Will
Patient is divided into two groups, i.e. treatment group and matched group, every group of 100 people.
Application process：Matched group smears the Western medicine compound of comparative example 1 preparation daily；It is real that treatment group smears the present invention daily
Apply the Western medicine compound of example 3 preparation, 2-3 time on the one, clean after once keeping 20 minutes, be within 15 days a course for the treatment of.
Remove acne print criterion of therapeutical effect：Effective, effectively and invalid.
(1) effective：After 2 courses for the treatment of of treatment, at acne print, skin is moistened, no depression, projection, no small pox trace, stops treatment
One month afterwards, no recur.
(2) effective：After 3 courses for the treatment of of treatment, at acne print, skin is moistened, and depression boss is inconspicuous, skin-color at acne print
Close to surrounding normal skin, after treating 4 courses for the treatment of, acne print symptom is wholly absent in pool, stops latter month for the treatment of, no recurs.
(3) invalid：After 3 courses for the treatment of of treatment, acne print quality take a favorable turn, but stops symptom after treatment and restore.
Therapeutic outcome is shown in Table 2：
This Western medicine compound of table 2 removes the efficacy result of acne print
| Group | Case load | Effective number of cases | Effectively number of cases | Invalid number of cases | Total effective rate |
| Matched group | 100 | 25 | 60 | 40 | 60% |
| Treatment group | 100 | 55 | 95 | 5 | 95% |
Table 2 shows, the Western medicine compound of the present invention passes through interpolation amprenavir and can be effectively increased the effective of removal acne print
Rate, effective percentage reaches 95%, and this Western medicine compound is a kind of Western medicine compound that safely and effectively can remove acne print.
This Western medicine compound passes through raw material and compounds performance synergism, can effectively suppress small pox growth, promote small pox to disappear
Scorching recovery, can effectively remove acne print, promote skin regeneration；And the Western medicine compound of the present invention adopt raw material be easy to get, cost
Low, good effect, smear conveniently, toxic and side effects little；In addition, being applied on normal skin with this Western medicine compound, skin can be made to become
Obtain moist, flexible.
Above the better embodiment of this patent is explained in detail, but this patent is not limited to above-mentioned embodiment party
Formula, in the ken that one skilled in the relevant art possesses, can also be on the premise of without departing from this patent objective
Make a variety of changes.
Claims (4)
1. a kind of Western medicine compound of preventing and treating comedo is it is characterised in that be made up of the raw material of following parts by weight：Hydroxytetracycline tablet
5-8 part, analgin tablet 3-5 part, normal saline 5-8 part, compound dexamethason acetate emulsifiable paste 3-5 part, fluocinonide cream 3-
10 parts, Loratadine Tablets 4-6 part, Retinoic acid 0.5-2 part, XUESAITONG PIAN 1-3 part, Nidus collocaliae 5-10 part, Aloe glue 1-3 part, miconazole
Emulsifiable paste 2-5 part, Oleum Helianthi 5-10 part, amprenavir 1-3 part.
2. the Western medicine compound of preventing and treating comedo according to claim 1 is it is characterised in that former by following parts by weight
Material composition：6 parts of hydroxytetracycline tablet, 4.5 parts of analgin tablet, 7 parts of normal saline, 4 parts of compound dexamethason acetate emulsifiable paste, acetic acid fluorine is light
4.5 parts of loose emulsifiable paste, 5 parts of Loratadine Tablets, 1 part of Retinoic acid, 1.5 parts of XUESAITONG PIAN, 8 parts of Nidus collocaliae, 1.5 parts of Aloe glue, miconazole breast
2.5 parts of cream, 7 parts of Oleum Helianthi, 2.5 parts of amprenavir.
3. a kind of preparation method of the Western medicine compound of described preventing and treating comedo as arbitrary in claim 1-2 it is characterised in that
Preparation method is as follows：
A. hydroxytetracycline tablet, analgin tablet, normal saline, compound dexamethason acetate emulsifiable paste, acetic acid fluorine are weighed by weight light
Loose emulsifiable paste, Loratadine Tablets, Retinoic acid, XUESAITONG PIAN, Nidus collocaliae, Aloe glue, miconazole emulsifiable paste, amprenavir and Oleum Helianthi, standby
With；
C. hydroxytetracycline tablet, analgin tablet, XUESAITONG PIAN, Loratadine Tablets are pulverized last mix homogeneously, obtain mixed powder
End；
D. by normal saline, compound dexamethason acetate emulsifiable paste, fluocinonide cream, miconazole emulsifiable paste, Nidus collocaliae, Aloe glue,
Retinoic acid, amprenavir mix homogeneously, obtain mix paste；
When e. Oleum Helianthi being put into vessel in heating to 30-45 DEG C, above-mentioned mixed-powder is put into above-mentioned mix paste
Mix in container, be sufficiently stirred for, ultrasonic vibration 5-10min, obtain final product paste Western medicine compound.
4. the preparation method of the Western medicine compound of preventing and treating comedo according to claim 3 is it is characterised in that by sunflower seed
When oil puts into vessel in heating to 35 DEG C, above-mentioned mixed-powder is put in container with above-mentioned mix paste and mixes, fully stir
Mix, ultrasonic vibration 8min, obtain final product paste Western medicine compound.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611032051.8A CN106389789A (en) | 2016-11-22 | 2016-11-22 | Western medicine composition for preventing and treating acne and preparation method of western medicine composition |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611032051.8A CN106389789A (en) | 2016-11-22 | 2016-11-22 | Western medicine composition for preventing and treating acne and preparation method of western medicine composition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106389789A true CN106389789A (en) | 2017-02-15 |
Family
ID=58083029
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201611032051.8A Withdrawn CN106389789A (en) | 2016-11-22 | 2016-11-22 | Western medicine composition for preventing and treating acne and preparation method of western medicine composition |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106389789A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110384744A (en) * | 2019-08-23 | 2019-10-29 | 张彬 | A kind of composition and preparation method treated scytitis and promote wound healing |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104056257A (en) * | 2014-06-24 | 2014-09-24 | 谢一泓 | Emulsifiable paste for treating acne |
-
2016
- 2016-11-22 CN CN201611032051.8A patent/CN106389789A/en not_active Withdrawn
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104056257A (en) * | 2014-06-24 | 2014-09-24 | 谢一泓 | Emulsifiable paste for treating acne |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110384744A (en) * | 2019-08-23 | 2019-10-29 | 张彬 | A kind of composition and preparation method treated scytitis and promote wound healing |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8846646B2 (en) | Topical treatment of skin infection | |
| EP2961418B1 (en) | Acne solution | |
| RU2007118663A (en) | METHOD FOR ADAPALENE SUPPORT FOR SUPPORT THERAPY OF AN ACID CRUSH | |
| CN102548564A (en) | Composition containing bee venom as an active ingredient for preventing and treating acne | |
| EP3342419B1 (en) | Acne-removing traditional chinese medicine composition and preparation method thereof | |
| NO171483B (en) | PROCEDURE FOR PREPARING A COSMETIC SKIN CARE PREPARATION FOR DIFFERENT ACN FORMS | |
| CN106389789A (en) | Western medicine composition for preventing and treating acne and preparation method of western medicine composition | |
| CN106377631A (en) | Western medicine composition for preventing and treating pimples | |
| CN106491876A (en) | A kind of pharmaceutical composition of prevention and treatment comedo | |
| 귀영박 | Pharmacological treatment options for acne | |
| EP2588095B1 (en) | Composition for the treatment of acne vulgaris | |
| CN105342905A (en) | Traditional Chinese medicinal facial mask | |
| US20130316017A1 (en) | Oral Composition for the Treatment of Acne | |
| US10071052B2 (en) | Method for the prevention and treatment of acne | |
| US9789078B2 (en) | Method of topically treating actinic keratosis with ingenol mebutate cycle therapy | |
| CN106822591A (en) | Compound acne-treating cream | |
| CN104434946A (en) | Compound drug for external use for treating acne | |
| Thomas et al. | High-dose vitamin A therapy for Darier's disease | |
| CN106619751A (en) | External medicine for treating tinea unguium | |
| WO2015164433A1 (en) | Acne solution | |
| Walling | Treatment options for the patient with acne vulgaris | |
| CN103285397A (en) | External compound medicine for treating acne | |
| Cunliffe | Retinoids and combination therapy | |
| CN106389236A (en) | Formula and preparation method of acne removing cream | |
| CN110013479A (en) | A kind of Chinese medicine composition for preventing and treating whelk |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WW01 | Invention patent application withdrawn after publication | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20170215 |